Search results for "Osteon"

showing 10 items of 236 documents

Medication related osteonecrosis of the jaws (MRONJ): Factors related to recurrence after treatment with surgery and platelet rich plasma (PRP) place…

2020

Background Medication-related osteonecrosis of the jaws (MRONJ) is a well-known complication associated with antiresorptive and antiangiogenic therapies. The purpose of this study was to analyse if there is any predictive factor of recurrence after local debridement plus platelet rich plasma (PRP) placement in MRONJ patients. Material and Methods Seventy MRONJ patients treated at the department of Oral and Maxillofacial Surgery in La Paz Hospital (Madrid, Spain) were included in this retrospective study. All of them were treated surgically by local debridement and PRP placement. The observation period was between January 2012 and January 2019. Information regarding use, type, administration…

medicine.medical_specialtyOsteoporosispain controlpain reliefBreast cancermedicineHumansGeneral DentistryMultiple myelomaalveolar osteitisUNESCO:CIENCIAS MÉDICASAgedRetrospective StudiestreatmentBone Density Conservation AgentsDiphosphonatesbusiness.industryPlatelet-Rich PlasmaResearchRetrospective cohort studyMiddle Agedmedicine.diseaseSurgeryZoledronic acidDenosumabOtorhinolaryngologydry socketJawOral and maxillofacial surgerySurgeryBisphosphonate-Associated Osteonecrosis of the JawFemaleOral SurgeryComplicationbusinessMultiple Myelomamanagementmedicine.drugMedicina oral, patologia oral y cirugia bucal
researchProduct

Photobiomodulation laser therapy in a Lenvatinib-related osteonecrosis of the jaw: A case report

2021

Background Medication-related osteonecrosis of the jaw (MRONJ) is a serious adverse drug reaction often presenting as a post-surgery complication that may interfere in the quality of the patient's life. In the last decade, additionally to bisphosphonates, other drugs have been associated with MRONJ including other antiresorptive, antiangiogenic or multitarget drugs such as levantinib. The data on MRONJ associated to lenvatinib is scarce with no guidelines for best management option. Our aim is to report a case of MRONJ associated with lenvatinib and the useful of a non-invasive management using local photobiomodulation (PBM) therapy with a 635nm diode laser. Material and methods A 61-year-o…

medicine.medical_specialtyPanoramic radiographOral Medicine and Pathologybusiness.industryCase Reportmedicine.diseaseSurgerychemistry.chemical_compoundQuality of lifechemistryMaxillamedicineComplicationLenvatinibOsteonecrosis of the jawbusinessGeneral DentistryOral medicineUNESCO:CIENCIAS MÉDICASAdverse drug reactionJournal of Clinical and Experimental Dentistry
researchProduct

2015

Recent data suggest that the traditional definition of bisphosphonate-associated osteonecrosis of the jaw (ONJ) may exclude patients who present with the non-exposed variant of the condition. To test the hypothesis that a proportion of patients with ONJ remain undiagnosed because their symptoms do not conform to the traditional case definition, we did a secondary analysis of data from MISSION (Multicentre study on phenotype, definition and classification of osteonecrosis of the jaws associated with bisphosphonates), a cross-sectional study of a large population of patients with bisphosphonate-associated ONJ who were recruited in 13 European centres. Patients with exposed and non-exposed ONJ…

medicine.medical_specialtyPediatricsBisphosphonate-associated osteonecrosis of the jawCross-sectional studybusiness.industryOsteoporosisLarge populationmedicine.diseaseSurgeryExact testOtorhinolaryngologySecondary analysisAntiresorptive AgentsmedicineSurgeryOral SurgeryOsteonecrosis of the jawbusinessBritish Journal of Oral and Maxillofacial Surgery
researchProduct

Kümmell's Disease: Clarifying the Mechanisms and Patients' Inclusion Criteria.

2014

The three major causes of vertebral body collapse include infection, malignant neoplasia, and trauma and it may be difficult to distinguish between them, particularly in the presence of severe osteoporosis. In 1891, however, Dr Hermann Kümmell, further added another possibility of vertebral body crush; the delayed posttraumatic collapse. As originally described, this rare clinical entity includes patients, who after a trivial trauma and an asymptomatic clinical course they develop a progressive vertebral body collapse and a painful kyphosis. Although more than a century has passed from its initial description, only few cases have been reported in the literature, whereas the main pathologic …

medicine.medical_specialtyPediatricsbusiness.industryKyphosisTime lagvertebral body collapseDiseasemedicine.diseaseAsymptomaticArticleSurgeryIntravertebral vacuum cleftresearch reviewKummell's diseasePathognomonicmedicineKümmell’s diseaseSevere osteoporosismedicine.symptomvertebral osteonecrosis.businessCollapse (medical)The open orthopaedics journal
researchProduct

Diabetes Mellitus and Its Association to the Occurrence of Medication-Related Osteonecrosis of the Jaw

2016

To date there is no consensus on the role of diabetes in the development of medication-related osteonecrosis of the jaws (MR-ONJ). Therefore, this study aimed to investigate the prevalence of diabetes and pathological glucose metabolism in patients with MR-ONJ compared to the general population. All maxillofacial surgery inpatients in one year at our department were investigated regarding diagnosis, anamnesis, medication, and blood glucose readings. 1374 records were analyzed. 35 patients with MR-ONJ were identified. Diabetics accounted for 14.3%. No significant difference in the prevalence of known diabetes was found, except for pathological glucose metabolism in patients with MR-ONJ (p &l…

medicine.medical_specialtyPopulationArticle03 medical and health sciences0302 clinical medicineInternal medicineDiabetes mellitusmedicinediabetes; hyperglycemia; bisphosphonates; denosumab; MR-ONJ; BP-ONJRisk factoreducationGeneral DentistryPathologicalbisphosphonatesAnamnesiseducation.field_of_studyBP-ONJdiabetesbusiness.industrySignificant differencedenosumab030206 dentistrymedicine.diseaseSurgerylcsh:RK1-715Denosumab030220 oncology & carcinogenesislcsh:DentistryMR-ONJhyperglycemiaOsteonecrosis of the jawbusinessmedicine.drugDentistry Journal; Volume 4; Issue 2; Pages: 17
researchProduct

Reply to Athanassios Kyrgidis, Zisis Teleioudis and Konstantinos Vahtsevanos’ Letter to the Editor re: Christian Walter, Bilal Al-Nawas, Knut A. Gröt…

2009

medicine.medical_specialtyProstate cancerBisphosphonate-associated osteonecrosis of the jawLetter to the editorbusiness.industryUrologyGeneral surgerymedicineAdvanced diseasebusinessmedicine.diseaseSurgeryEuropean Urology
researchProduct

A pragmatic window of opportunity to minimise the risk of MRONJ development in individuals with osteoporosis on Denosumab therapy: a hypothesis

2021

Abstract Denosumab is associated with the development of medication-related osteonecrosis of the jaw (MRONJ), an uncommon but severe oral side effect with a higher prevalence in metastatic cancer patients than in patients with metabolic bone fragility. Although several oral triggers can initiate MRONJ, invasive oral treatments and tooth extraction still remain the most common precipitating event. In general, tooth extraction and oral surgery should be avoided in patients at increased risk of MRONJ, while extraction of non-restorable teeth should be performed based on specific risk reduction protocols to eliminate dental/periodontal infections, still protecting from MRONJ onset. Based on th…

medicine.medical_specialtySide effectOsteoporosisSpecialties of internal medicine030209 endocrinology & metabolismMRONJOral surgery tooth extraction03 medical and health sciences0302 clinical medicineOral surgeryMedication-related osteonecrosis of the jawmedicineDenosumab osteoporosis; Medication-related osteonecrosis of the jaw; MRONJ; Oral surgery tooth extraction; Denosumab; Diphosphonates; Humans; Bisphosphonate-Associated Osteonecrosis of the Jaw; Bone Density Conservation Agents; OsteoporosisHumansIntensive care medicineGeneral Dentistrytooth extractionBisphosphonate-associated osteonecrosis of the jawDiphosphonatesBone Density Conservation Agentsbusiness.industryHypothesismedicine.diseaseosteoporosisDenosumab osteoporosisBone Density Conservation Agentsstomatognathic diseasesDenosumabOtorhinolaryngologyRC581-951030220 oncology & carcinogenesisDental surgeryOral and maxillofacial surgeryBisphosphonate-Associated Osteonecrosis of the JawNeurology (clinical)DenosumabbusinessOsteonecrosis of the jawmedicine.drugHead & Face Medicine
researchProduct

Prognosis factors in the treatment of bisphosphonate-related osteonecrosis of the jaw - Prognostic factors in the treatment of BRONJ -

2014

Objectives: Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is a relatively rare but serious side effect of bisphosphonate (BP)-based treatments. This retrospective study aimed to investigate the risk factors and predictive markers in cases where patients were refractory to a recommended conservative treatment offered in our hospital. Patients and Methods: This single-center study collated the medical records of all patients treated for BRONJ between 2004 and 2011. A complete medical history, including detailed questionnaires, was collected for all patients, focusing on identifying underlying risk factors, clinical features, location and bone marker levels of BRONJ. Results: The mea…

medicine.medical_specialtySide effectbusiness.industryMedical recordmedicine.medical_treatmentResearchRetrospective cohort studyOdontologíaBisphosphonatemedicine.disease:CIENCIAS MÉDICAS [UNESCO]Ciencias de la saludSurgeryN-terminal telopeptideInternal medicineUNESCO::CIENCIAS MÉDICASMedicineMedical historyOral SurgerybusinessOsteonecrosis of the jawGeneral DentistryProgressive disease
researchProduct

Osteonecrosis of the jaws in patients assuming oral bisphosphonates for osteoporosis: A retrospective multi-hospital-based study of 87 Italian cases

2013

Abstract Background Bisphosphonates (BPs) are currently the chief drugs for the prevention/treatment of osteoporosis; one of their adverse effects is the osteonecrosis of the jaw (BRONJ). The primary endpoints of this multi-center cross-sectional study are: i) an observation of the clinical features of BRONJ in 87 osteoporotic, non-cancer patients; and ii) an evaluation of their demographic variables and comorbidities. Methods 87 BRONJ patients in therapy for osteoporosis with BPs from 8 participating clinical Italian centers were consecutively identified and studied. After BRONJ diagnosis and staging, comorbidities and data relating to local and drug-related risk factors for BRONJ were col…

medicine.medical_specialtyTime FactorsMultivariate analysisHeart DiseasesOsteoporosisSettore MED/50 - Scienze Tecniche Mediche ApplicateAdministration OralMandibleOsteonecrosis jawHospital based studyAdrenal Cortex HormonesRisk FactorsSettore MED/28 - Malattie OdontostomatologicheInternal medicineDiabetes MellitusInternal MedicinemedicineHumansIn patientRisk factorOral bisphopshonateAdverse effectOsteoporosis PostmenopausalAgedRetrospective StudiesAged 80 and overAlendronateBone Density Conservation AgentsDiphosphonatesbusiness.industryLiver DiseasesIncidence (epidemiology)Age FactorsMiddle Agedmedicine.diseaseSurgeryCross-Sectional StudiesItalyOral bisphopshonates; Osteonecrosis jaws; OsteoporosisHypertensionMultivariate AnalysisOsteoporosisBisphosphonate-Associated Osteonecrosis of the JawFemaleOsteonecrosis of the jawbusiness
researchProduct

Osteoporosis and bisphosphonates-related osteonecrosis of the jaw: Not just a sporadic coincidence-a multi-centre study

2011

Abstract Introduction Bisphosphonates (BPs) are powerful drugs that inhibit bone metabolism. Adverse side effects are rare but potentially severe such as bisphosphonate-related osteonecrosis of the jaw (BRONJ). To date, research has primarily focused on the development and progression of BRONJ in cancer patients with bone metastasis, who have received high dosages of BPs intravenously. However, a potential dilemma may arise from a far larger cohort, namely the millions of osteoporosis patients on long-term oral BP therapy. Patients and methods This current study assessed 470 cases of BRONJ diagnosed between 2004 and 2008 at eleven different European clinical centres and has resulted in the …

medicine.medical_specialtyTime FactorsSettore MED/09 - Medicina Internamedicine.medical_treatmentOral Surgical ProceduresOsteoporosisAdministration OralSettore MED/28 - Malattie OdontostomatologicheInternal medicinemedicineHumansMedical historyAdverse effectBone Density Conservation AgentsDiphosphonatesDose-Response Relationship Drugbusiness.industryContraindicationsOsteonecrosisBisphosphonatemedicine.diseaseSurgeryZoledronic acidOtorhinolaryngologyCohortOral and maxillofacial surgeryOsteoporosisSurgeryOral Surgeryosteoporosis bisphosphonates ostenecrosis jawsOsteonecrosis of the jawbusinessJaw Diseasesmedicine.drug
researchProduct